Coverage by:

Shaw and Partners

Darren Vincent

Bell Potter

 Tanushree Jain

H.C. Wainwright & Co.

 Joseph Pantginis

BELL POTTER

4 November 2019

FDA Fast Track's BNC210 for PTSD

Analyst: Tanushree Jain

BELL POTTER

26 September 2019

Positive PK study de-risks BNC210

Analyst: Tanushree Jain 

BELL POTTER

20 September 2019

FDA supportive, BNO on the right path for BNC210

Analyst: Tanushree Jain

BELL POTTER

20 August 2019

Underlying FY19 Result below our forecast

Analyst: Tanushree Jain

BELL POTTER

20 February 2019

BNO gets another shot at PTSD with lead drug BNC210

Analyst: Tanushree Jain

BELL POTTER

4 October 2018

Licensing propects still intact for BNC210 following PTSD disappointment

Analyst: Tanushree Jain

BLUE OCEAN EQUITIES

30 August 2018 

Initiation of Coverage: Chill Out ..... Won't Be Long Now. BNC210. Elegant. Novel. Welcomed.

Analyst: Michael Gerges

  • Edison

    29 August 2018

    PTSD programme on track for results in Q3

    Analysts: Nathaniel Calloway, Maxim Jacobs

    Download PDF

  • Shaw & Partners

    17 August 2018

    Licensing and Trial Results Remain the Key Catalysts Awaited Rather than FY18 Results

    Download PDF

  • H.C. Wainwright & Co

    31 July 2018

    Prepping for Post-Labor Day Party; Previewing Major Catalyst; Reiterate Buy

    Analyst: Joseph Pantginis

    Download PDF

  • Edison

    17 July 2018

    RESTORE trial completed, data this quarter.

    Analysts:  Nathaniel Calloway, Maxim Jacobs

    Download PDF

  • Hardman & Co

    04 June 2018

    A big deal on oncolgy?

    Analysts: Martin Hall, Dorothea Hill, Grégoire Pavé

    Download PDF

  • Hardman & Co

    30 May 2018

    Third Phase II trial of BNC210 begins

    Analysts: Martin Hall, Dorothea Hill, Grégoire Pavé

    Download PDF

  • Edison

    29 May 2018

    Phase IIa in agitation of the elderly initiated

    Analysts: Nathaniel Calloway, Maxim Jacobs

    Download PDF

  • H.C. Wainwright & Co

    23 May 2018

    BNC210 Profile Continues to Expand With Third Phase 2 Initiation; Reiterate Buy

    Analysts: Joseph Pantginis, Pete Stavropoulos

    Download PDF

  • H.C. Wainwright & Co

    17 April 2018

    BNC210 Has Us Feeling Positive about Phase 2 PTSD Data Readout

    Anaylsts: Joseph Pantginis, Pete Stavropoulos

    Download PDF

BELL POTTER

13 April 2018

Flashnote: New data on non-core oncology assets should assist ongoing monetisation process

Analyst: Tanushree Jain

BELL POTTER

11 April 2018

Flashnote: Phase 2 PTSD trial completes recruitment 

Analyst: Tanushree Jain

BELL POTTER

14 February 2018

Expecting a catalyst rich 2HCY18 for BNO

Analyst: Tanushree Jain 

  • Hardman & Co

    09 February 2018

    Channelling expertise in CNS Drugs

    Analysts: Martin Hall, Dorothea Hill, Gregoire Pave

    Download PDF

  • H.C. Wainwright & Co

    17 January 2018

    We Project Calming PTSD Data Midyear and Bigger Things After That: Reiterate Buy

    Analysts: Joseph Pantginis, Pete Stavropoulos

    Download PDF

  • Shaw and Partners

    24 November 2017

    BNC101 Shows More Encouraging Results Ahead of its Expected Monetisation

    Analysts: Darren Vincent, Matthew Johnston

    Download PDF

BELL POTTER 

2 November 2017

Initial Phase 1 BNC101 data should assist ongoing partnering discussions

Analyst: Tanushree Jain 

BELL POTTER

18 August 2017

FY17 results ahead of our forecasts 

Analyst: Tanushree Jain

  • H.C. Wainwright & Co.

    17 August 2017

    FY17 Results: BNC210 Excitement Continues to Grow for CNS; Oncology Visibility Soon Could Help BD Efforts; Reiterate Buy

    Analyst: Joseph Pantginis

    Download PDF

  • Rodman & Renshaw

    13 July 2017

    Management Meetings Continue to Highlight Disconnect Across Pacific: Reiterate Buy

    Analyst: Joseph Pantginis

    Download PDF

  • Shaw and Partners

    28 April 2017

    3Q17; Merck Payments, Immuno-Oncology progress & 210 Negotiations

    Analyst: Darren Vincent

    Download PDF

  • Rodman & Renshaw

    27 March 2017

    Our Chat Points to Very Active Partnering Discussions; Analyst Day Recap;

    Reiterate Buy

    Analyst: Joseph Pantginis

    Download PDF

  • Rodman and Renshaw

    20 March 2017

    Initiating Coverage:

    We Feel Lots Calmer Talking BNC210 and Bionomics: Initiating at Buy With A$2 PT

    Analyst: Joseph Pantginis

    Download PDF

BELL POTTER

22 February 2017

We continue to see deep value

Analyst: Tanushree Jain 

BELL POTTER

6 February 2017

CNS franchise validated, US$10m milestone triggered on initiation of trial by Merck

Analyst: Tanushree Jain

BELL POTTER

22 September

BNC210 Shines in Phase 2 GAD Trial, Partnering Prospects Strengthen

Analyst: Tanushree Jain 

BELL POTTER

5 September 2016

Strong Turnaround prospects, we see deep value

Analyst: Tanushree Jain

BELL POTTER

30 June 2016

BNC210 program expanded with start of PTSD trial

Analyst: Tanushree Jain

BELL POTTER

24 June 2016

On track to report General Anxiety Disorder trial results in 3Q16

Analyst: Tanushree Jain

BELL POTTER

16 June 2016

Bionomics announces new Board appointments

Anaylst: Tanushree Jain

BELL POTTER

2 May 2016

BNC105 looks well-suited for an immuno-oncology combination study

Analyst:  Tanushree Jain

BELL POTTER

2 March 2016

Long terms growth prospects intact, stock oversold

Analyst: Tanushree Jain

BELL POTTER 

8 December 2015

BNO raises capital to fund new Phase II BNC210 trial

Analyst: Tanushree Jain 

BELL POTTER

8 October 2015

Merck becomes a shareholder, Pain collaboration extended

Analyst: Tanushree Jain

BELL POTTER

29 September 2015

Bionomics Strengthens its Board

Analyst: Tanushree Jain

BELL POTTER

3 August 2015

Bionomics Strengthens its Executive Team

Analyst: Tanushree Jain

BELL POTTER

16 June 2015

BNC105 and immuno-oncology therapies - a synergistic combination

Analyst: Tanushree Jain

BELL POTTER

4 June 2015

BNC210 - A potential blockbuster in making

Analyst: Tanushree Jain

BELL POTTER

27 February 2015

New BNC105 Biomarker data builds confidence

Analyst: Tanushree Jain

BELL POTTER

29 September 2014

New BNC105 Biomarker data increase its attractiveness

Analyst: Tanushree Jain